08:48 AM EDT, 08/13/2026 (MT Newswires) -- Candel Therapeutics ( CADL ) reported a Q2 net loss Thursday of $0.52 per diluted share, widening from a loss of $0.09 a year earlier.

Analysts surveyed by FactSet expected a loss of $0.23.

As expected, no revenue was reported for the quarter ended June 30.

Operating expenses totaled $26.7 million, up from $11.2 million a year ago.

As of June 30, the company had $201.6 million in cash and cash equivalents, which it said is sufficient to fund operations through Q1 2028.